Amgen (NASDAQ:AMGN) Now Covered by Barclays

Barclays began coverage on shares of Amgen (NASDAQ:AMGN) in a report issued on Friday morning,Benzinga reports. The firm issued an equal weight rating and a $350.00 target price on the medical research company’s stock.

A number of other equities analysts have also commented on AMGN. Morgan Stanley boosted their price objective on Amgen from $304.00 to $309.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 4th. UBS Group lifted their price objective on Amgen from $380.00 to $390.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Piper Sandler boosted their price target on shares of Amgen from $381.00 to $432.00 and gave the stock an “overweight” rating in a research note on Wednesday. HSBC restated a “buy” rating and issued a $425.00 price objective on shares of Amgen in a report on Wednesday, December 10th. Finally, Wall Street Zen lowered shares of Amgen from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 7th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Amgen currently has a consensus rating of “Moderate Buy” and a consensus target price of $351.76.

Amgen Stock Down 0.2%

Shares of NASDAQ:AMGN opened at $374.75 on Friday. Amgen has a 52 week low of $261.43 and a 52 week high of $385.12. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The company’s fifty day moving average is $343.21 and its 200-day moving average is $316.20. The company has a market capitalization of $202.02 billion, a PE ratio of 26.34, a P/E/G ratio of 3.80 and a beta of 0.46.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. During the same quarter in the prior year, the firm earned $5.31 EPS. The firm’s quarterly revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities research analysts predict that Amgen will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be paid a $2.52 dividend. The ex-dividend date of this dividend is Friday, February 13th. This is a boost from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 annualized dividend and a yield of 2.7%. Amgen’s payout ratio is currently 70.84%.

Institutional Trading of Amgen

Large investors have recently made changes to their positions in the company. Sunbelt Securities Inc. lifted its holdings in Amgen by 6.1% during the fourth quarter. Sunbelt Securities Inc. now owns 7,546 shares of the medical research company’s stock worth $2,470,000 after acquiring an additional 432 shares in the last quarter. Cambient Family Office LLC bought a new stake in shares of Amgen in the fourth quarter worth about $737,000. Hamilton Wealth LLC acquired a new stake in shares of Amgen during the fourth quarter worth about $234,000. Compound Planning Inc. lifted its holdings in shares of Amgen by 37.1% during the 4th quarter. Compound Planning Inc. now owns 9,377 shares of the medical research company’s stock valued at $3,069,000 after purchasing an additional 2,537 shares in the last quarter. Finally, Claris Financial LLC bought a new position in shares of Amgen during the 4th quarter valued at about $248,000. Institutional investors own 76.50% of the company’s stock.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Rothschild & Co Redburn says Amgen’s stock price is expected to rise — a bullish analyst view that could support upside if reiterated or joined by others. Amgen (NASDAQ:AMGN) Stock Price Expected to Rise, Rothschild & Co Redburn Analyst Says
• Neutral Sentiment: Amgen priced $4.0 billion of senior unsecured notes across multiple maturities — this increases debt but provides liquidity; impact depends on use of proceeds (buybacks, M&A, refinancing). Investors should watch tenor and coupon details to assess financing cost and leverage effects. Amgen Prices $4 Billion Senior Unsecured Notes Offering
• Neutral Sentiment: Amgen has been a “trending” ticker on sites like Zacks and Yahoo — heightened attention can lift liquidity and volatility but is not a directional fundamental catalyst by itself. Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: “Here’s What the Street is Saying” roundups summarize mixed analyst commentary — useful for context but check individual firm views for conviction and PTs. Here’s What the Street is Saying About Amgen Inc. (AMGN)
• Neutral Sentiment: Short-interest data reported for mid-February appears to show 0 shares (NaN/incomplete) and a 0.0 days-to-cover metric — likely a reporting glitch; no reliable evidence here of a significant short squeeze or increase in bearish positioning.
• Negative Sentiment: Barclays initiated coverage with an “equal-weight” rating and a $350 price target, implying roughly a mid-single-digit downside from recent levels — this new coverage (and PT below the current price) is a near-term headwind for sentiment. Barclays initiates coverage of Amgen (AMGN) with equal-weight recommendation

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.